Hikma Pharmaceuticals Plc Directorate Change (7201P)
February 22 2016 - 4:52AM
UK Regulatory
TIDMHIK
RNS Number : 7201P
Hikma Pharmaceuticals Plc
22 February 2016
Hikma Appoints John Castellani to Board of Directors
London, 22 February 2016 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ("Hikma"), the FTSE 100 pharmaceuticals company, today
announces the appointment of Mr. John J. Castellani as an
independent non-executive director of the Company with effect from
1 March 2016. Mr. Castellani will join the Audit, Remuneration and
Compliance, Responsibility and Ethics (CRE) Committees.
Said Darwazah, Chairman and Chief Executive of Hikma, said: "I
am delighted that John will join our Board. He brings a wealth of
pharmaceutical regulatory and policy experience, particularly in
the United States, as well as broad business experience. His
background and expertise will further enhance our strong
Board."
John J. Castellani
Mr. Castellani was President and Chief Executive Officer of
Pharmaceutical Research and Manufacturers of America (PhRMA) from
2010 to 2015. Prior to that, he was the President and Chief
Executive of Business Roundtable, an association of leading US
company Chief Executives. During his career Mr. Castellani has also
held senior positions with Burson-Marsteller, Tenneco, Inc. and
General Electric Corp., amongst others.
Mr. Castellani is also a member of the board of trustees of The
Johns Hopkins Medical System Sibley Memorial Hospital in
Washington, DC, and a member of the board of directors of the
National Patient Safety Foundation.
Mr. Castellani holds a Batchelor of Science Degree (Biology)
from Union College Schenectady, New York.
There is no other information required to be disclosed in
respect of Mr. Castellani's appointment under LR 9.6.13R of the
Listing Rules.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC +44 (0)20 7399
Peter Speirs, Company Secretary 2772
Susan Ringdal, Vice President, Corporate +44 (0)20 7399
Strategy & Investor Relations 2760
FTI Consulting +44 (0)20 3727
Ben Atwell / Matthew Cole 1000
Notes to Editors:
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million. Hikma is a constituent of the FTSE 100 index of
companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPGUBCPUPQUBP
(END) Dow Jones Newswires
February 22, 2016 04:52 ET (09:52 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024